PANCRELIPASE

Other

Brand names: Creon

Oral

Mechanism of Action

12.1 Mechanism of Action Pancreatic enzyme products contain a mixture of lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglyceride, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltriose in the duodenum and proximal small intestine, thereby acting like digestive enzymes physiologically secreted by the pancreas.

Indications

See full prescribing information

Contraindications

• 4 CONTRAINDICATIONS None. None ( 4 )

FDA Warnings

5 WARNINGS AND PRECAUTIONS Fibrosing C olonopathy : Associated with high doses, usually over prolonged use and in pediatric patients with cystic fibrosis
3 ) Risk of Viral Transmission: The presence of porcine viruses that might infect humans cannot be definitely excluded
If symptoms occur, initiate appropriate medical management; consider the risks and benefits of continued treatment
Fibrosing colonopathy is a rare, serious adverse reaction initially described in association with use of high-dose pancreatic enzyme products, usually over a prolonged period of time and most commonly reported in pediatric patients with cystic fibrosis

Known Side Effects

9 documented side effects by frequency

Diarrhea

>10%

Nausea

1-10%

Weight Loss

1-10%

Fatigue

1-10%

Abdominal Pain

1-10%

Vomiting

1-10%

Shortness of Breath

1-10%

Drug Not Working

0.1-1%

General Unwellness

0.1-1%

Community Discussions

No community discussions found for PANCRELIPASE yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Oral